Merck Just Made Kidney Cancer's Best Drug Even Better
The FDA just approved the first checkpoint inhibitor plus HIF-2α inhibitor combo for post-surgery kidney cancer. Merck's KEYTRUDA + WELIREG beat KEYTRUDA alone in a landmark trial, and Wall Street sees a potential $6 billion peak opportunity.
The Only Drug That Worked Just Got a Wingman
Imagine you're a kidney cancer patient. Your surgeon just removed the tumor. Scans are clean. But here's the uncomfortable truth: depending on your risk profile, there's a real chance the cancer comes back.
For the past few years, patients in this situation had exactly one proven option to lower that risk: Merck's blockbuster immunotherapy, KEYTRUDA (pembrolizumab). It worked. But oncologists kept asking the same question: could we do better?
Now the FDA has answered. The agency approved KEYTRUDA in combination with WELIREG (belzutifan) as a post-surgery treatment for patients with clear cell renal cell carcinoma (the most common type of kidney cancer) who face an intermediate-high or high risk of their cancer returning. It's the first time a checkpoint inhibitor has been paired with an HIF-2α inhibitor in this setting, and the clinical data suggest the combo is worth the added complexity.
Beating the Winner Is Hard. Merck Did It Anyway.
To appreciate what happened here, you need to understand how unusual this trial design was.
Most cancer drug trials compare a new treatment against a placebo or the current standard of care. That's a relatively low bar. Merck's Phase 3 trial, called LITESPARK-022, did something much harder: it compared the KEYTRUDA + WELIREG combo against KEYTRUDA alone. In other words, Merck bet it could beat its own best-selling drug.
The trial enrolled 1,841 patients who had their kidneys (or tumors) surgically removed and were at elevated risk of recurrence. Half got KEYTRUDA plus WELIREG. The other half got KEYTRUDA plus a placebo.
The result? The combination cut the risk of cancer recurrence or death by 28% compared to KEYTRUDA alone. At two years, 80.7% of patients on the combo remained disease-free, versus 73.7% on KEYTRUDA solo. That seven-percentage-point gap might sound modest on paper, but in a population where the alternative was already the only proven adjuvant therapy, it's genuinely meaningful.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
This is the first adjuvant kidney cancer trial to show a benefit over an active immunotherapy, not just over a sugar pill. Think of it like a sprinter breaking a world record that was already considered untouchable.
Two Drugs, Two Different Attacks
So why does adding WELIREG help? The answer lies in how the two drugs attack cancer from completely different angles.
KEYTRUDA is a PD-1 inhibitor. It works by removing the "cloak" that cancer cells use to hide from the immune system. Once that disguise is stripped away, the body's own T-cells can find and kill tumor cells. Think of it as turning the floodlights on a burglar.
WELIREG targets something called HIF-2α, a protein that acts like a growth switch in clear cell kidney cancer. When the VHL gene (a tumor suppressor) is broken, which happens in most clear cell RCC tumors, HIF-2α goes into overdrive. It tells cancer cells to grow blood vessels, multiply, and survive. WELIREG jams that switch into the "off" position.
By combining immune activation (KEYTRUDA) with a direct hit on tumor biology (WELIREG), Merck essentially built a two-front war against microscopic cancer cells that might be lurking after surgery.
The Safety Trade-Off
More drugs usually means more side effects, and this combo is no exception. The key toxicities flagged in the trial include anemia, elevated liver enzymes, and low oxygen levels (hypoxia). These are known risks for both drugs individually, so the safety profile wasn't surprising. But it does mean oncologists will need to monitor patients more closely than with KEYTRUDA monotherapy.
The dosing regimen is also worth noting: patients take WELIREG as a daily pill (120 mg) alongside KEYTRUDA infusions every three or six weeks, for up to about a year. Merck also secured approval for KEYTRUDA QLEX, a subcutaneous (under-the-skin) version of pembrolizumab, giving patients a needle-free IV alternative.
Why Wall Street Is Paying Close Attention
KEYTRUDA is already the world's top-selling drug, with consensus estimates around $32.7 billion in 2026 revenue. But Merck faces a looming problem: KEYTRUDA's key patents will eventually expire, and the company needs new indications and combinations to keep the franchise growing.
This is where the adjuvant kidney cancer approval gets interesting from a business perspective.
SVB Leerink analyst Daina Graybosch previously estimated that adding WELIREG to Merck's adjuvant kidney cancer portfolio could nearly triple the company's expected revenue in that line of care to more than $6 billion at peak. That's partly because WELIREG's list price (roughly $30,000 per month) is about twice that of KEYTRUDA, and the 54-week adjuvant course creates a substantial revenue opportunity per patient.
For 2026 specifically, don't expect fireworks. The mid-year approval means only a partial year of sales, and physician adoption takes time. The real revenue acceleration should arrive in 2027 and beyond as the combo becomes standard practice.
The Competitive Landscape Is Getting Crowded
Merck currently owns the only approved HIF-2α inhibitor on the market, which gives it a head start. But the competition is gearing up.
Arcus Biosciences is developing casdatifan, a next-generation HIF-2α inhibitor showing early combo data with cabozantinib (an Exelixis drug). Phase 3 first-line kidney cancer trials are planned for 2026. Meanwhile, Bristol-Myers Squibb remains a checkpoint inhibitor heavyweight through nivolumab-based regimens but doesn't own an HIF-2α drug, leaving it dependent on partners.
Merck's structural advantage is hard to overstate: it controls both the PD-1 backbone and the HIF-2α inhibitor in-house. That vertical integration means faster trial design, simpler regulatory filings, and no profit-sharing headaches. Competitors building cross-company combinations will have to navigate partnership complexity that Merck simply doesn't face.
What This Means for Patients
For the roughly 80,000 Americans diagnosed with kidney cancer each year, this approval expands the menu of options at a critical moment: right after surgery, when the window to prevent recurrence is still open.
The combo won't be right for everyone. Patients at lower risk of recurrence, those with non-clear-cell histology, or those concerned about the added side effects may still opt for KEYTRUDA alone or active surveillance. And the big question that remains unanswered is whether the disease-free survival benefit will eventually translate into longer overall survival. That data is still maturing.
But for high-risk patients staring down the possibility of recurrence, having a second weapon in the arsenal isn't just a nice-to-have. It could be the difference between staying cancer-free and facing round two.
5 min read
The Lung Cancer Drug Where Half the Patients Are Still Winning After 7 Years
Seven years into a clinical trial, more than half of metastatic lung cancer patients on Pfizer's lorlatinib still haven't progressed. Oncologists are starting to whisper the word "cure," and the data might actually justify it.
